Key terms
About ARDX
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARDX news
Apr 12
3:26pm ET
Ardelyx call volume above normal and directionally bullish
Apr 05
9:38am ET
Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
Apr 05
6:27am ET
Ardelyx initiated with an Outperform at Leerink
Mar 26
2:26pm ET
Ardelyx call volume above normal and directionally bullish
Mar 25
8:12am ET
Ardelyx appoints Mike Kelliher as EVP, corporate development, strategy
Mar 13
1:55pm ET
Ardelyx put volume heavy and directionally bearish
Mar 05
3:25pm ET
Ardelyx call volume above normal and directionally bullish
Mar 05
2:27pm ET
Jefferies sees 10%-15% upside for Ardelyx if HR-5074 bill passes
Feb 23
8:40am ET
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)
Feb 23
6:16am ET
Ardelyx’s Growth Trajectory: Buoyant Sales Projections and Market Expansion Drive Buy Rating
Feb 23
6:10am ET
Ardelyx price target raised to $13 from $11 at H.C. Wainwright
Feb 22
7:25pm ET
Ardelyx’s Ibsrela and Xphozah: Strong Sales and Growth Outlook Justify Buy Rating
Feb 22
4:06pm ET
Ardelyx reports Q4 EPS (12c), consensus (9c)
Feb 22
2:19pm ET
Ardelyx options imply 12.6% move in share price post-earnings
Feb 21
10:07pm ET
After a Significant Stock Run, Market Awaits Ardelyx’s (NASDAQ:ARDX) Q4 Earnings
Feb 21
8:11am ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), NeoGenomics (NEO) and Ardelyx (ARDX)
Feb 02
12:25pm ET
Ardelyx call volume above normal and directionally bullish
Jan 31
10:35am ET
Ardelyx put volume heavy and directionally bearish
Jan 22
2:21pm ET
Analysts’ Top Healthcare Picks: Ardelyx (ARDX), Generation Bio (GBIO)
Jan 18
9:40am ET
Unusually active option classes on open January 18th
Jan 17
12:25pm ET
Ardelyx call volume above normal and directionally bullish
No recent press releases are available for ARDX
ARDX Financials
Key terms
Ad Feedback
ARDX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARDX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
